col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


26 Ergebisse       Seite 1

 [1] 
Wiley: Journal of Cellular Biochemistry
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Feb―23 Decoding SARS-CoV-2 Inhibition: Insights From Molecular Dynamics Simulation of Condensed Amino Thiourea Scaffold Small Molecules Xiaoli Shen, Hao Zhang, Pengyin Zhang, Xuerui Zhao, Chang Liu, Jianan Ju, et al. (+2)
2 [GO] 2024―Jul―07 SARS-CoV-2 Spike Protein Induces Time-Dependent CTSL Upregulation in HeLa Cells and Alveolarspheres Magdalena M. Bolsinger, Alice Drobny, Sibylle Wilfling, Stephanie Reischl, Florian Krach, Raul Moritz, et al. (+9)
3 [GO] 2024―Apr―09 Obesity-dependent molecular alterations in fatal COVID-19: A retrospective postmortem study of metabolomic profile of adipose tissue Bruna I. Pilger, Alex Castro, Franciane F. Vasconcellos, Karen F. Moura, Étore De Favari Signini, Luis Felipe B. Marqueze, et al. (+12)
4 [GO] 2024―Feb―13 Intrinsic factors behind long COVID: IV. Hypothetical roles of the SARS-CoV-2 nucleocapsid protein and its liquid-liquid phase separation Ahmed Eltayeb, Faisal Al-Sarraj, Mona Alharbi, Raed Albiheyri, Ehab H. Mattar, Isam M. Abu Zeid, et al. (+5)
5 [GO] 2024―Jan―29 DON/DRP-104 as potent serine protease inhibitors implicated in SARS-CoV-2 infection: Comparative binding modes with human TMPRSS2 and novel therapeutic approach Ernest Oduro-Kwateng, Mahmoud E. Soliman
6 [GO] 2023―Dez―15 Intrinsic factors behind long COVID: III. Persistence of SARS-CoV-2 and its components Nawal Abd El-Baky, Amro A. Amara, Vladimir N. Uversky, Elrashdy M. Redwan
7 [GO] 2023―Nov―24 Intrinsically disordered proteins and liquid-liquid phase separation in SARS-CoV-2 interactomes Lazar M. Vasović, Gordana M. Pavlović-Lažetić, Jovana J. Kovačević, Miloš V. Beljanski, Vladimir N. Uversky
8 [GO] 2023―Okt―07 Intrinsic factors behind long-COVID: II. SARS-CoV-2, extracellular vesicles, and neurological disorders Yousra A. El-Maradny, Alberto Rubio-Casillas, Kareem I. Mohamed, Vladimir N. Uversky, Elrashdy M. Redwan
9 [GO] 2023―Jul―12 Probing the binding nature and stability of highly transmissible mutated variant alpha to omicron of SARS-CoV-2 RBD with ACE2 via molecular dynamics simulation Jaganathan Ramakrishnan, Archana Chinnamadhu, Suganya Suresh, Kumaradhas Poomani
10 [GO] 2023―Apr―26 Structural insights into SARS-CoV-2 main protease conformational plasticity Budheswar Dehury, Sarbani Mishra, Sanghamitra Pati
11 [GO] 2023―Jan―07 The role of S477N mutation in the molecular behavior of SARS-CoV-2 spike protein: An in-silico perspective Mozhgan Mondeali, Ali Etemadi, Khabat Barkhordari, Mina Mobini Kesheh, Sara Shavandi, Atefeh Bahavar, et al. (+3)
12 [GO] 2022―Jul―15 Beneficial effect of polyphenols in COVID-19 and the ectopic F 1 F O -ATP synthase: Is there a link? Isabella Panfoli, Alfonso Esposito
13 [GO] 2022―Mai―27 Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor Surabhi Lata, Mohd. Akif
14 [GO] 2022―Apr―06 Covidin, a possible new player between hepcidin and ferroportin in hypoxia and inflammation caused by COVID-19 Giorgio Biasiotto, Fabiana Ferrari
15 [GO] 2022―Mrz―28 Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19 Pallab Kar, Md. Moshfekus Saleh-E-In, Nishika Jaishee, Akash Anandraj, Emil Kormuth, Balachandar Vellingiri, et al. (+7)
16 [GO] 2022―Feb―08 A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2 Ismail Celik, Trina E. Tallei
17 [GO] 2022―Jan―17 Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients Prakash Jha, Prithvi Singh, Shweta Arora, Armiya Sultan, Arnab Nayek, Kalaiarasan Ponnusamy, et al. (+3)
18 [GO] 2022―Jan―08 Iron dysregulation in COVID-19 and reciprocal evolution of SARS-CoV-2: Natura nihil frustra facit Yash Gupta, Dawid Maciorowski, Brian Medernach, Daniel P. Becker, Ravi Durvasula, Claudia R. Libertin, Prakasha Kempaiah
19 [GO] 2021―Nov―16 SARS-CoV-2 spike evolutionary behaviors; simulation of N501Y mutation outcomes in terms of immunogenicity and structural characteristic Neda Rostami, Edris Choupani, Yaeren Hernandez, Seyed S. Arab, Seyed M. Jazayeri, Mohammad M. Gomari
20 [GO] 2021―Nov―06 Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine Manisha Choudhury, Anantha K. Dhanabalan, Nabajyoti Goswami
21 [GO] 2021―Okt―21 Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts Theo Rein
22 [GO] 2021―Sep―13 Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation Eileen Socher, Marcus Conrad, Lukas Heger, Friedrich Paulsen, Heinrich Sticht, Friederike Zunke, Philipp Arnold
23 [GO] 2021―Jun―23 Recent advances in antibody-based immunotherapy strategies for COVID-19 Abdolreza Esmaeilzadeh, Samaneh Rostami, Pegah M. Yeganeh, Safa Tahmasebi, Majid Ahmadi
24 [GO] 2021―Mai―16 Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus Maryam Ajami, Mahboobeh Nazari, Habibollah mahmoodzadeh, Seyed Mohammad Moazzeni
25 [GO] 2021―Feb―23 Tetracycline as an inhibitor to the SARS-CoV-2 Tom Y. Zhao, Neelesh A. Patankar
26 [GO] 2020―Jul―21 Stem cell therapies for COVID-19: Strategy and application Radbod Darabi, Yong Li
 [1] 

26 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec